WINTON GROUP Ltd Sells 8,900 Shares of Vericel Co. (NASDAQ:VCEL)

WINTON GROUP Ltd cut its stake in shares of Vericel Co. (NASDAQ:VCEL) by 36.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,340 shares of the biotechnology company’s stock after selling 8,900 shares during the quarter. WINTON GROUP Ltd’s holdings in Vericel were worth $842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP lifted its holdings in shares of Vericel by 214.0% during the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company’s stock worth $24,837,000 after acquiring an additional 400,667 shares during the last quarter. Stifel Financial Corp lifted its stake in Vericel by 40.0% during the third quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company’s stock worth $1,186,000 after purchasing an additional 8,020 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Vericel by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock worth $48,768,000 after purchasing an additional 9,613 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of Vericel by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock valued at $1,312,000 after purchasing an additional 200 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in Vericel in the 3rd quarter worth approximately $563,000.

Wall Street Analyst Weigh In

Several research analysts have commented on VCEL shares. Canaccord Genuity Group lifted their price target on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. Stephens restated an “overweight” rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial reiterated a “buy” rating and issued a $61.00 price objective (down previously from $67.00) on shares of Vericel in a report on Monday, March 3rd. Finally, StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and a consensus target price of $62.29.

Insider Activity

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the transaction, the director now owns 26,595 shares in the company, valued at $1,662,187.50. The trade was a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Dominick Colangelo sold 26,592 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the completion of the sale, the chief executive officer now owns 259,997 shares of the company’s stock, valued at $11,902,662.66. This trade represents a 9.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,092 shares of company stock valued at $1,683,582. Company insiders own 5.20% of the company’s stock.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $44.50 on Friday. The stock’s 50-day moving average is $53.23 and its 200 day moving average is $51.73. The company has a market cap of $2.23 billion, a PE ratio of 741.79 and a beta of 1.78. Vericel Co. has a 1 year low of $39.12 and a 1 year high of $63.00.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.